日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

靶向FGFR信号通路可克服致癌性PIK3CA驱动的浆液样子宫内膜癌的治疗耐药性和免疫逃逸。

Cheng, Xin; Qian, Changli; Holdridge, Erica; Ananda, Guruprasad; Jiang, Tao; Zhang, Yadong; Ni, Jing; Xie, Shaozhen; Gu, Hao; Ji, Renlei; Ivanova, Elena V; Nucci, Marisa R; Wang, Zhe; Chen, Kaifu; Kochupurakkal, Bose; Freeman, Gordon J; Shapiro, Geoffrey I; Liu, Joyce; Konstantinopoulos, Panagiotis A; Matulonis, Ursula; Zhao, Jean J

Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial

来曲唑、阿贝西利和二甲双胍治疗子宫内膜癌:一项非随机 II 期试验

Konstantinopoulos, Panagiotis A; Zhou, Ningxuan; Penson, Richard T; Le, Tien V; Campos, Susana; Krasner, Carolyn; Wright, Alexi A; Porter, Rebecca; Horowitz, Neil; Bouberhan, Sara; Liu, Joyce F; Hindenach, Sarah; Sawyer, Hannah; Koppermann, Lani; Hayes, Martin; Polak, Madeline; Shea, Meghan; Widick, Page; Cheng, Su-Chun; Castro, Cesar; Beumer, Jan H; Matulonis, Ursula A; Lee, Elizabeth K

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

比较度伐利尤单抗、奥拉帕尼和西地尼布单药治疗、联合治疗或化疗治疗既往接受过贝伐珠单抗治疗的铂耐药卵巢癌患者的疗效:II期NRG-GY023试验

Lee, Jung-Min; Miller, Austin; Rose, Peter G; AlHilli, Mariam; Washington, Christina; John, Veena S; Shah, Chirag A; Matsuo, Koji; Siedel, Jean; Miller, David S; Hopp, Elizabeth E; O'Shea, Andrea; Chan, John K; Bradford, Leslie S; Morse, Christopher B; Nagel, Christa I; Rodabaugh, Kerry J; Kohn, Elise C; Moore, Kathleen N; Liu, Joyce F

Machine Learning-Assisted False Positive Detection in Metabolite Identification Workflows

机器学习辅助代谢物鉴定工作流程中的假阳性检测

Adàlia, Ramon; Cifuentes, Paula; Liu, Joyce; Cheruzel, Lionel; Sanjuan, Gemma; Margalef, Tomàs; Zamora, Ismael

Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8(+) and PD-1(+) Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors

机构层面的免疫分析表明,肿瘤内CD8(+)和PD-1(+)细胞数量高可预测主要癌症类型患者的更高生存率,且与主要风险因素无关。

Alessi, Joao V; Lindsay, James R; Giobbie-Hurder, Anita; Sharma, Bijaya; Felt, Kristen; Kumari, Priti; Mazor, Tali; Cerami, Ethan; Lotter, William; Altreuter, Jennifer; Weirather, Jason; Dryg, Ian; Hoebel, Katharina; Manos, Michael; Adib, Elio; Curtis, Jennifer D; Ricciuti, Biagio; Di Federico, Alessandro; Ghandour, Fatme; Saad, Eddy; Wang, Xin-An; Pecci, Federica; Holovatska, Marta; Gandhi, Malini M; Hughes, Melissa E; O'Meara, Tess A; Chan, Sabrina J; Pfaff, Kathleen; Konstantinopoulos, Panagiotis A; Hodi, F Stephan; Shipp, Margaret A; Signoretti, Sabina; Choueiri, Toni; Wei, Xiao X; Santagata, Sandro; Hanna, Glenn J; Lin, Nancy U; Tolaney, Sara M; Liu, Joyce; Sorger, Peter K; Lindeman, Neal; Sholl, Lynette M; Nowak, Jonathan A; Barbie, David; Awad, Mark M; Johnson, Bruce E; Rodig, Scott J

Non-Invasive Laser Surgery With Deep Operating Depth Using Multibeam Interference

利用多光束干涉技术实现深层手术的非侵入性激光手术

Liu, Joyce

Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma

Wee1抑制剂adavosertib治疗复发性子宫癌肉瘤的II期研究

Cham, Stephanie; Xiong, Niya; Tayob, Nabihah; Krasner, Carolyn; Wright, Alexi A; Lee, Elizabeth K; Sawyer, Hannah; Mathews, Cara; Konstantinopoulos, Panagiotis A; Matulonis, Ursula A; Liu, Joyce F

Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X(L) degradation to overcome cancer chemoresistance.

紫杉醇诱导的有丝分裂停滞导致细胞凋亡依赖性的趋同,而这种趋同可以通过 BCL-X(L) 降解来安全地利用,从而克服癌症的化疗耐药性

Qin Xingping, Presser Adam, Johnson Lissah, Matoba Yusuke, Shay Brendan S, Xu Weiyi, Choiniere Jonathan, Fraser Cameron, Garbicz Filip, Spetz Johan, Yu Stacey, Florido Mary H C, Picucci Francesca, Yang Yang, Drapkin Ronny, Carrasco Ruben, Hill Sarah J, Liu Joyce, Matulonis Ursula, Brugge Joan, Rueda Bo R, Zhou Daohong, Stover Elizabeth H, Sarosiek Kristopher A

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

鲁索替尼联合一线新辅助治疗晚期卵巢癌的I期和随机II期研究:NRG肿瘤协作组研究

Landen, Charles N; Buckanovich, Ronald J; Sill, Michael W; Mannel, Robert S; Walker, Joan L; DiSilvestro, Paul A; Mathews, Cara A; Mutch, David G; Hernandez, Marcia L; Martin, Lainie P; Bishop, Erin; Gill, Sarah E; Gordinier, Mary E; Burger, Robert A; Aghajanian, Carol; Liu, Joyce F; Moore, Kathleen N; Bookman, Michael A

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

纳维托克和曲美替尼联合抑制BCL-xL和MEK治疗KRAS或NRAS突变晚期实体瘤的I/II期研究

Corcoran, Ryan B; Do, Khanh T; Kim, Jeong E; Cleary, James M; Parikh, Aparna R; Yeku, Oladapo O; Xiong, Niya; Weekes, Colin D; Veneris, Jennifer; Ahronian, Leanne G; Mauri, Gianluca; Tian, Jun; Norden, Bryanna L; Michel, Alexa G; Van Seventer, Emily E; Siravegna, Giulia; Camphausen, Kyle; Chi, Gary; Fetter, Isobel J; Brugge, Joan S; Chen, Helen; Takebe, Naoko; Penson, Richard T; Juric, Dejan; Flaherty, Keith T; Sullivan, Ryan J; Clark, Jeffrey W; Heist, Rebecca S; Matulonis, Ursula A; Liu, Joyce F; Shapiro, Geoffrey I